Patients With High-grade Pancreatic Neuroendocrine Tumors
Status:
ENROLLING_BY_INVITATION
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
* Pancreatic neuroendocrine tumor (pNET) is a rare form of cancer. Treatment options such as hormonal therapy (octreotide) and targeted therapy (everolimus and sunitinib) may be considered for grade 1 or 2 pNETs; however, cytotoxic chemotherapy is essential in cases with grade 3 pNETs or pNECs.
* Cisplatin/etoposide remains the treatment of choice for high-grade pNET/pNEC. Other irinotecan-based therapies, such as FOLFIRI (cisplatin/irinotecan), FOLFOX, and temozolomide capecitabine, have been employed; however, a standard of care remains to be established.
Phase:
PHASE2
Details
Lead Sponsor:
National Cancer Center, Korea
Collaborators:
Gangnam Severance Hospital Samsung Medical Center Seoul National Hospital Seoul National University Bundang Hospital